Stay updated with breaking news from Lyell Immunopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $2.74, but opened at $2.61. Lyell Immunopharma shares last traded at $2.63, with a volume of 60,857 shares. Analyst Ratings Changes Separately, HC Wainwright reissued a “buy” rating and issued […]
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22
Lyell Immunopharma (NASDAQ: ) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to…
06.05.2024 - Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced ...
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The